Europe
Collaboration prioritizes scientific innovation and social change to one day eliminate lung cancer as a cause of death
PHARMASEAL, a new provider of clinical trial management and governance solutions to enter the market, announces a second major release of its EngilityÔ CTMS platform.
Second clinical trial of Pill Connect system to be undertaken through University of Groningen following successful trial of prototypes with major CRO
Drug discovery expert will be responsible for developing Domain’s platforms and driving technology-based projects to support Domain’s development and growth
NeoPhore Limited, a small molecule cancer immuno-oncology company, announces the appointment of Dr Matthew Baker as VP Immunology to the company’s management team.
Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment
Ascension Healthcare plc announces it will be attending the 27th International Society of Thrombosis and Haemostasis Congress, taking place in Melbourne, Australia, from Saturday 6th July to Wednesday 10th July.
Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.
PRESS RELEASES